Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

DXCM vs IDXX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

DXCM Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

DXCM Overall Winner 6-Pillar Tally: DXCM 4 – 2 IDXX Matrix Metrics: DXCM 5 – 5 IDXX

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Idexx Laboratories Inc (IDXX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas IDXX carries 44.3/100 (HOLD) at $676.21 (40.0x Forward P/E, 32.5% operating margin).

  • Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile IDXX trades in a Markup technical trend (SURGE options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About DXCM vs IDXX
DXCM NASDAQ Head-to-Head Winner
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap $29.9B
TTM Revenue $5.10B
Forward P/E 25.3x
Beta / 30D Vol 0.59β · 43% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 49.0 Fund 56.0 Flow 68.0 Mom 54.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.3%), weak momentum, RSI 43
RSI-14: 43.0 · SMA20: $81.49 · SMA50: $83.94
IDXX NASDAQ
Idexx Laboratories Inc
In Vitro & In Vivo Diagnostic Substances
$676.21
-1.95% 1D
Market Cap $54.3B
TTM Revenue $4.66B
Forward P/E 40.0x
Beta / 30D Vol 0.61β · 81% Vol
Unified Composite Score
44.3 / 100 HOLD
Tech 23.0 Fund 48.0 Flow 70.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (8.8% over 20 days), RSI 60
RSI-14: 59.7 · SMA20: $658.69 · SMA50: $579.87

6-Pillar Scorecard Institutional Category Breakdown (DXCM 4 – 2 IDXX)

Columns: Metric · DXCM · IDXX
1. Valuation Multiples DXCM
Forward P/E 25.3x 40.0x
Trailing P/E 31.6x 46.5x
PEG Ratio 1.30x 3.24x
EV / Revenue 5.9x 11.8x
2. Growth & Scale DXCM
Revenue Growth (YoY) +11.2% +9.9%
Earnings Growth (YoY) +2.6% +17.9%
TTM Revenue (USD) $5.10B $4.66B
Market Cap $29.9B $54.3B
3. Profitability & Quality IDXX
Gross Margin 63.4% 62.7%
Operating Margin 24.0% 32.5%
Net Profit Margin 19.4% 25.4%
Return on Equity (ROE) 37.7% 68.9%
4. Balance Sheet & Cash Flow DXCM
Cash Generation (TTM) $1.73B $1.30B
Cash Flow Margin 33.9% 27.9%
Net Cash / Leverage $432M Net Debt (0.55x D/E) $775M Net Debt (0.52x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning IDXX
Options Structure Phase CONSOLIDATION SURGE
Current IV / %ile 63.0% (15th %ile) 81.5% (34th %ile)
Put/Call OI Skew 0.48x (Call-Skewed) 0.15x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Markdown DISTRIBUTION · Markup
6. R&D & Supply-Chain Moat DXCM
OpEx & R&D Intensity 39.4% of Rev ($2.01B) 30.2% of Rev ($1.41B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat High-Margin Pricing Power Moat
Supply-Chain Role Medical Devices Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: DXCM (5) vs IDXX (5)
Institutional Metric DXCM IDXX Criterion Row Edge
Market Capitalization
Scale
$29.9B $54.3B Larger Scale IDXX
Trailing P/E Ratio
Valuation
31.6x 46.5x Lower Multiple DXCM
Forward P/E Ratio
Valuation
25.3x 40.0x Lower Multiple DXCM
Revenue Growth (YoY)
Growth
+11.2% +9.9% Higher Growth DXCM
Operating Margin (TTM)
Profitability
24.0% 32.5% Higher Margin IDXX
Net Profit Margin
Profitability
19.4% 25.4% Higher Margin IDXX
Return on Equity (ROE)
Capital Efficiency
37.7% 68.9% Higher ROE IDXX
52-Week Range Position
Momentum
63% ($57–$93) 65% ($501–$770) Stronger Trend IDXX
Beta / 30D Volatility
Risk Regime
0.59β · 43% Vol 0.61β · 81% Vol Lower Realized Risk DXCM
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 44.3 / 100 (HOLD) Higher Composite DXCM
Trailing 12M Revenue (USD)
Operating Scale
$5.10B $4.66B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
63.4% 62.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.30x PEG · 5.9x EV/Rev 3.24x PEG · 11.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.73B ($432M Net Debt (0.55x D/E)) $1.30B ($775M Net Debt (0.52x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IDXX +18.03 pp
DXCM: +1.28% · IDXX: +19.31%
3M Horizon IDXX +33.75 pp
DXCM: -12.89% · IDXX: +20.86%
6M Horizon IDXX +10.88 pp
DXCM: +10.01% · IDXX: +20.89%
1Y Horizon DXCM +35.8 pp
DXCM: +32.8% · IDXX: -3.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period DXCM Revenue IDXX Revenue DXCM Op. Margin IDXX Op. Margin Margin Leader
FY2018 $1.03B $2.21B -18.1% 22.2% IDXX
FY2019 $1.48B $2.41B 9.6% 23.0% IDXX
FY2020 $1.93B $2.71B 15.5% 25.7% IDXX
FY2021 $2.45B $3.22B 10.9% 29.0% IDXX
FY2022 $2.91B $3.37B 13.4% 26.7% IDXX
FY2023 $3.62B $3.66B 16.5% 30.0% IDXX
FY2024 $4.03B $3.90B 14.9% 29.0% IDXX
FY2025 $4.66B $4.30B 19.6% 31.6% IDXX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
DXCM CONSOLIDATION
73d in phase · OBV ACCUMULATION
Current IV 63.0%
IV Percentile 15th %ile
Put/Call OI Skew 0.48x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact DXCM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
IDXX SURGE
9d in phase · OBV DISTRIBUTION
Current IV 81.5%
IV Percentile 34th %ile
Put/Call OI Skew 0.15x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IDXX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $81.61 · IV 39.6%

DXCM vs. IDXX: Simulated 5-Day Option Payoffs & Capital Efficiency

Compare 100 shares of DXCM ($8,161) vs. IDXX ($68,965) against risk-defined 5-day vertical and put-wall option structures.

DXCM Spot $81.61 · IV 39.6%
DXCM Options Simulator →
5-DAY BULLISH SWING Liq B

Dec 18 $80 / $90 Bull Call Spread

Buy 1x $80C · Sell 1x $90C · 31d

Net Entry $482 Debit
T+5d @ +5% Move +$136 (+28%)
Max Risk / Buffer $482 Capped
5d Edge & Liquidity 0.7x R:R · Liq B
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq B

Dec 18 $75 / $70 Bull Put Spread

Sell 1x $75P · Buy 1x $70P · 31d

Net Entry $86 Credit
Max Credit / Yield +$86 (+20.8% RoM)
Max Risk / Buffer -9.2% Cushion ($414 Mgn)
5d Edge & Liquidity 78% PoP · Liq B
Simulate 5-Day Payoff →
IDXX Spot $689.65 · IV 32.4%
IDXX Options Simulator →
5-DAY BULLISH SWING Liq C

Dec 18 $700 / $740 Bull Call Spread

Buy 1x $700C · Sell 1x $740C · 28d

Net Entry $610 Debit
T+5d @ +5% Move +$796 (+130%)
Max Risk / Buffer $610 Capped
5d Edge & Liquidity 1.6x R:R · Liq C
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq C

Dec 18 $660 / $600 Bull Put Spread

Sell 1x $660P · Buy 1x $600P · 28d

Net Entry $837 Credit
Max Credit / Yield +$837 (+16.2% RoM)
Max Risk / Buffer -5.5% Cushion ($5,163 Mgn)
5d Edge & Liquidity 73% PoP · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
DXCM Moat Profile High-Margin Pricing Power Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $29.9B market capitalization and 24.0% operating margin.
OpEx & R&D Reinvestment 39.4% of Rev ($2.01B)
90D Engineering Disclosures 0 Published
IDXX Moat Profile High-Margin Pricing Power Moat
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $54.3B market capitalization and 32.5% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($1.41B)
90D Engineering Disclosures 0 Published

Investor FAQ DXCM vs IDXX Key Questions & Quantitative Answers

As of Nov 20, 2026, DexCom, Inc. (DXCM) is the stronger overall head-to-head candidate over Idexx Laboratories Inc (IDXX) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Balance Sheet & Cash Flow). DXCM carries a Unified Composite Score of 50.8/100 (HOLD) at $79.32 (25.3x Forward P/E, 24.0% operating margin), whereas IDXX carries 44.3/100 (HOLD) at $676.21 (40.0x Forward P/E, 32.5% operating margin). Technical & Structure Timing Caution: DXCM is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 43.0); meanwhile IDXX trades in a Markup technical trend (SURGE options phase, RSI 59.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXCM leads the Growth & Scale pillar: DXCM posts +11.2% YoY revenue growth and +2.6% YoY earnings growth on $5.10B TTM revenue (63.4% gross margin, 24.0% operating margin), compared with IDXX at +9.9% YoY revenue growth and +17.9% YoY earnings growth on $4.66B TTM revenue (62.7% gross margin, 32.5% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DXCM cumulative revenue shifted +352.4% while IDXX shifted +94.6%. In operating R&D and SG&A reinvestment, DXCM deploys 39.4% of Rev ($2.01B) (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($1.41B) (0 disclosures) for IDXX.

DXCM screens cheaper on headline valuation multiples. DXCM trades at 25.3x Forward P/E, 31.6x Trailing P/E, 1.30x PEG, and 5.9x EV/Revenue (33.9% FCF margin), whereas IDXX trades at 40.0x Forward P/E, 46.5x Trailing P/E, 3.24x PEG, and 11.8x EV/Revenue (27.9% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DXCM (37.7% ROE) versus IDXX (68.9% ROE) capital efficiency.

In options market volatility and institutional positioning, DXCM carries 63.0% implied volatility (15th %ile, Compressed (<25th %ile)), a 0.48x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.59β · 43% Vol realized risk). By comparison, IDXX carries 81.5% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.15x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.61β · 81% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.